By Stylianos Katsoulakis
Since 2015, when my grandfather Stelios passed away with terminal Chronic Obstructive Pulmonary Disease (COPD), I have started developing a sincere interest for medicine and how technology advancements in this field can help patients like him to prolong their lives and enjoy more quality time with their grandchildren. Regenerative medicine appears to be one of such breakthrough advancements.
Although still with lack of consensus on a precise definition, regenerative medicine is generally considered the branch of biomedical science focused on “developing therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure.”
Based on general consensus, the field consists of four main segments (i) Stem-cell therapies, where either autologous cells or cells from a different donor (allogeneic) are used to recreate or repair ailing, wounded or dysfunctional tissues like in iPSC-linked retinal regeneration for blind patients (ii) Tissue engineering, that is the combination of scaffolds, cells and active molecules to generate new functional tissues such as new skin for major burns (iii) Biofabrication else called 3D bioprinting, which is the automated manufacturing of tissues and organs in precise 3D structures such as the 3D tissue patches for the heart or the 3D organs like the bladder and the mini-liver and (iv) Gene therapies, which is the modification and repair of faulty genes responsible for certain, mainly inherited, conditions such as sickle-cell disease and beta-thalassemia.
The global market for regenerative medicine has been estimated at 36 billion USD in 2024 with North America representing 49% of it. It is projected to reach 213 billion USD in 2034 with a ten-tear CAGR of 20% driven by both, scientific breakthroughs and growing demand for personalized, biologically integrated therapies particularly in North America and Asia-Pacific regions. Increasing prevalence of chronic ailments and growing incidence of genetic disorders are key contributors to this growth. In terms of product segments, stem-cell therapies account for 57% of the market with tissue engineering contributing an additional 29%. From a therapeutic area perspective, musculoskeletal and wound-healing accounted for almost two-thirds of the market in 2024 although Oncology and Rare Diseases are expected to have the highest growth in the future.
Despite the market size and the high growth rates, only a small fraction of people who need regenerative medicine can have it with such shortage presenting one of today’s biggest healthcare challenges. According to the Global Observatory on Donation and Transplantation (GODT), “only 10% of the global demand for transplants is met each year”. For example, in United States alone in the year 2023, there were as many as 90,000 patients in waiting list for kidney transplantation, yet only 28,000 such operations took place during the year. The need is even higher given that those in waiting list are the healthier of the diagnosed patients with higher chance of survival while there are many more patients either undiagnosed or in more serious condition such as the End-Stage Kidney Disease (ESKD), who are not wait-listed.
In that context, the looming question is whether scientific advances in regenerative medicine will, eventually, enable the replacement of traditional medical devices such as transplants, thereby meeting the exponentially growing medical demand for these solutions. To address such question, we will examine the pros and cons of each alternative.
From one side, traditional medical devices are well-studied and regulated with decades of clinical data and rather predictable outcomes supporting them. They are manufactured and distributed at scale with physicians being familiar with them making them implementable in many more healthcare centers and hospitals. At the same time though, they do not address the root-cause of the problem and can not restore original tissue or organ function but rather improve the underlying problem while requiring maintenance or replacement over-time not to mention the devices’ infection risks. As an example, the first coronary stent was implanted in 1986 and, thirty years later, more than 2 million of such procedures are performed globally every year with most of them lasting less than one hour. Still though and despite technology and clinical improvements, 5-10% of the patients need new stents soon after their first operation.
On the other side, regenerative medicine offers an innovative approach with a potential for true tissue healing and, if successful, a significant reduction or even elimination of the need for lifelong devices, medications or recurring interventions. At the same time though, it is associated with higher costs while its novelty and development complexity put incremental regulatory hurdles with lengthier clinical trials and slower approval processes. Also, there are no long-term outcome studies on the integration with host tissue while rejections or other unwanted results are not known in longer-term. As an indicative example, for heart diseases including coronary artery disease, there are 241 clinical trials assessed although only 7.5% of them lasting for more than 10 years , a clear sign that there is still a long way before the long-term benefit of such therapies can be clearly established.
At the same time though, there are a few diseases for which regenerative medicine can offer solutions, even though experimental, while traditional medical devices or drugs can not. For example, patients with optical nerve damage due to trauma or hereditary conditions, may enrol in early-phase clinical trials using injected stem cells. In certain trials, more than 50% of patients reported improvement in their vision along multiple dimensions when now, there are no other therapeutic options. In pulmonology also, there is a lot of research and some trials in early stages trying to improve outcomes for IPF or COPD patients at their terminal stages by stimulating stem cells for lung tissue regeneration or by developing 3D printed lung scaffolds. In every case though, such solutions as well as similar research in other therapeutic areas are several years or even decades before commercialization.
Like most technological advancements in the past, there are financial aspects and economic trade-offs that cannot be ignored. Regenerative medicine requires significant upfront investment in research and development, which is expected to be higher than that of drugs – as a benchmark, an oncology drug may require an R&D cost between 1 billion USD and 4 billion USD for development and launch. At the same time, due to its high complexity and tailor-made approach, the cost to produce and distribute such solutions cannot benefit much from economies of scale. Treatments with regenerative medicine will also require specialized facilities and highly trained scientific personnel which further increases the required investment. Lastly, we shall not ignore the unpredictability of its acceptance from the healthcare professionals and the patients alike, a risk for which investors and companies will require higher return for their money.
In addition to the economical aspect, there are several concerns from a scientific, ethical and regulatory perspective that shall be also considered.
From a scientific perspective, many researchers warn for tumour-generation risks given that regenerative medicine refers to living products and, as such, they may mutate or proliferate without control some years after the initial operation. The risk to clinical trial participants shall be also considered, particularly for 3D bioengineered organs given the lack of vascular tissues which, in turn, causes the death of cells because of absence of oxygen and nutrients. From a regulatory standpoint, one of the biggest concerns is the fragmented global standards, with different agencies like FDA, EMA or MHRA having different approval frameworks for such therapy pathways. In contrast to the CE mark standard for medical devices, agencies have blur and many times, unclear lines for regenerative medicine given its overlap between drugs, biologics and medical devices. Another regulatory concern is that stem cells and 3D manufactured tissues are not easy to produce, distribute and store at scale consistently. Last but not the least, there are ethical questions like where the line lies between therapy and human enhancement (e.g., “edited immunity”). Of ethical concern is also the potential inequality in access to these therapies as many of them are very expensive and require high specialization to implement thus limiting these therapies to wealthy individuals in high-income countries.
As a conclusion, regenerative medicine is at its initial stages and presents a bright promise for the patients with terminal diseases, hereditary conditions or irreversible traumas and a great opportunity for investors and pharma companies in the longer term. To reach there though, there are several challenges that need to be addressed from a scientific, regulatory and ethical point of view while also working to find the right balance between financial viability for the investors and therapy affordability for the patients.
With the memories of my grandfather Stelios always in my thoughts, I truly hope that the challenges faced currently by regenerative medicine are addressed swiftly and effectively so that more grandchildren enjoy unique moments with their beloved ones!